InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-23.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Gros David-Alexandre C, Chairman & CEO. Insider active across 1 company, notably Eledon Pharmaceuticals, Inc.. Aggregated, 6 reports have been published. Breakdown: 6 buys · 0 sell. Total volume traded: €98k. Activity tracked since 9 June 2021. The latest transaction was disclosed on 20 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
2,000 shares@ US$4.488.1% of flowCommon StockSEC:0000899243-21-049171
Ideal exit: 16 Sept 2022 (T+270)
2,000 shares@ US$4.480.0070% mcap8.1% of flowCommon StockSEC:0000899243-21-049171:0
Ideal exit: 16 Sept 2022 (T+270)
4,000 shares@ US$6.210.019% mcap21.7% of flowCommon StockSEC:0001209191-21-052519:0
Ideal exit: 14 May 2022 (T+270)
4,000 shares@ US$6.2121.7% of flowCommon StockSEC:0001209191-21-052519
Ideal exit: 14 May 2022 (T+270)
3,000 shares@ US$8.010.017% mcap20.2% of flowCommon StockSEC:0000899243-21-022998:0
Ideal exit: 6 Mar 2022 (T+270)
3,000 shares@ US$8.0120.2% of flowCommon StockSEC:0000899243-21-022998
Ideal exit: 6 Mar 2022 (T+270)
6 of 6 declarations
About Gros David-Alexandre C
David-Alexandre C. Gros is Chief Executive Officer at Eledon Pharmaceuticals, Inc. He leads the company and oversees all operations, ensuring compliance and financial performance. His leadership is essential for the growth and development of the organization.
